Autopsy report · NCT04504435
Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants
Cause of deathOther
“Further development of GSK3494245 has been halted based on assessment of clinical data indicating that predicted efficacious doses cannot be achieved in line with dosing requirements outlined in the target product profile for the proposed indication.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 3 years 4 months before it stopped.
- 59 participants enrolled.
- Results were posted on the registry 2 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Industry
- Conditions
- Leishmaniasis
- Interventions
- GSK3494245; Placebo
- Participants
- 59
- Sites
- 1
- Countries
- United Kingdom
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.